Today Vimian Group signed an agreement to acquire Bova Holdings Limited (Bova), a leading companion animal health specialty pharmaceuticals company in the United Kingdom. The company offers customised specialty pharmaceuticals for companion animals.
Established in 2017, Bova offers specialty pharmaceuticals covering a wide and expanding range of product classes. The company has more than 100 specialty pharmaceutical formulations, all raw materials and products are compliant with quality standards set out by regulatory authorities and the pharmaceuticals industry. Bova serves veterinary clinics and hospitals across the UK and in ten additional European markets through an online ordering system with deliveries within 24 hours.
Nick Bova, founder and CEO of Bova, will continue to lead the company as part of Nextmune and Vimian.
The Board of Directors of Vimian Group AB has based on the authorisation from the Annual General Meeting on 2 June 2023, resolved on a rights issue of up to approximately SEK 1,633 million. The purpose of the Rights Issue
Read moreOn the 22 of February, the winners of the “CEO of the Year” award were announced at Kistamässan in Stockholm. The winner in the Large-Cap category was David von Laskowski, Picadeli & Greenfood Group. “CEO of the Year” has been
Read moreVegner Group Limited is a leading residential property management group in the UK with 475 employees, over 100,000 homes under management and a nationwide reach across 20 office locations. Vegner specializes in serving Residents Management Company (RMC) clients, bringing further
Read more